NTEC - Intec Pharma jumps 65% after research pact with UK based GW Pharma

Intec Pharma (NTEC) entered into a feasibility agreement with London based, GW Research to explore using the Accordion Pill ((AP)) platform for an undisclosed research program.The complete details of the agreement are undisclosed."Through partnerships such as this, we continue to evaluate the utility of our Accordion Pill platform in the development of innovative therapeutics," says Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.Shares are up 64.5% PM.

For further details see:

Intec Pharma jumps 65% after research pact with UK based GW Pharma